{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:35Z","timestamp":1791308195076,"version":"4.3.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.lungcan.2009.07.016","type":"journal-article","created":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T05:54:36Z","timestamp":1252562076000},"page":"455-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Inhibition of mesothelin\u2013CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy"],"prefix":"10.1016","volume":"68","author":[{"given":"Raffit","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun F.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2009.07.016_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2009.07.016_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lungcan.2009.07.016_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib4","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2009.07.016_bib5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0021-9258(17)42180-6","article-title":"A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5","volume":"269","author":"Yamaguchi","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lungcan.2009.07.016_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2009.07.016_bib10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2009.07.016_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2009.07.016_bib12","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-213X-3-2","article-title":"Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells","volume":"3","author":"Prieve","year":"2003","journal-title":"BMC Dev Biol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib14","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lungcan.2009.07.016_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.lungcan.2009.07.016_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lungcan.2009.07.016_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004347-198303000-00005","article-title":"Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125","volume":"2","author":"Kabawat","year":"1983","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00931312","article-title":"CA 125 in the serum and tissue of patients with gynecological disease","volume":"241","author":"Fuith","year":"1987","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.lungcan.2009.07.016_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","article-title":"Immunohistochemical marker panels for distinguishing between epitheloid mesothelioma and lung adenocarcinoma","volume":"57","author":"Kushitani","year":"2007","journal-title":"Pathol Int"},{"key":"10.1016\/j.lungcan.2009.07.016_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2559.1996.d01-562.x","article-title":"Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression","volume":"30","author":"Bateman","year":"1997","journal-title":"Histopathology"},{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2009.07.016_bib21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ijgc-00009577-200511001-00015","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.lungcan.2009.07.016_bib22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthemic perfusion","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000217960","article-title":"Importance of serum CA 125 levels in malignant peritoneal mesothelioma","volume":"17","author":"Simsek","year":"1996","journal-title":"Tumour Biol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib24","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16","volume":"276","author":"Yin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lungcan.2009.07.016_bib25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000064032","article-title":"The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure","volume":"23","author":"O\u2019Brien","year":"2002","journal-title":"Tumour Biol"},{"key":"10.1016\/j.lungcan.2009.07.016_bib26","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun"},{"key":"10.1016\/j.lungcan.2009.07.016_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lungcan.2009.07.016_bib28","series-title":"Presented at the 44th ASCO annual meeting, developmental therapeutics: molecular therapeutics session","article-title":"A phase I study of MORAb-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer","author":"Laheru","year":"2008"},{"key":"10.1016\/j.lungcan.2009.07.016_bib29","first-page":"414","article-title":"False elevation of serum CA-125 level caused by human anti-mouse antibodies","volume":"32","author":"Bertholf","year":"2002","journal-title":"Ann Clin Lab Sci"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500209004292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500209004292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:19:35Z","timestamp":1759234775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500209004292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0169500209004292"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2009.07.016","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of mesothelin\u2013CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2009.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}